[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1118629T1 - Εμβολιο ιου ερπητα ζωστηρα - Google Patents

Εμβολιο ιου ερπητα ζωστηρα

Info

Publication number
CY1118629T1
CY1118629T1 CY20171100188T CY171100188T CY1118629T1 CY 1118629 T1 CY1118629 T1 CY 1118629T1 CY 20171100188 T CY20171100188 T CY 20171100188T CY 171100188 T CY171100188 T CY 171100188T CY 1118629 T1 CY1118629 T1 CY 1118629T1
Authority
CY
Cyprus
Prior art keywords
shepherd
virtual
virus vaccine
vzv
adjuvant
Prior art date
Application number
CY20171100188T
Other languages
English (en)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118629(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of CY1118629T1 publication Critical patent/CY1118629T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Χρήση ανοσογονικής σύνθεσης που περιλαμβάνει VZV gE ή ανοσογονικό θραύσμα αυτού και ΤΗ-1 ανοσοενισχυτικό στην παρασκευή φαρμάκου για την πρόληψη ή ανακούφιση από έρπητα ζωστήρα ή/και μεθερπητική νευραλγία. Επίσης αξιώνονται συνθέσεις οι οποίες περιλαμβάνουν ακρωτηριασμένο VZV gE αντιγόνο και ανοσοενισχυτικό που περιέχει QS21, χοληστερόλη και 3D MPL.
CY20171100188T 2005-03-03 2017-02-10 Εμβολιο ιου ερπητα ζωστηρα CY1118629T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine
EP20060707446 EP1858917B8 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine

Publications (1)

Publication Number Publication Date
CY1118629T1 true CY1118629T1 (el) 2017-07-12

Family

ID=34430592

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20151100179T CY1116108T1 (el) 2005-03-03 2015-02-20 Εμβολιο ιου ερπητα ζωστηρα
CY20171100188T CY1118629T1 (el) 2005-03-03 2017-02-10 Εμβολιο ιου ερπητα ζωστηρα
CY20181100637T CY1120347T1 (el) 2005-03-03 2018-06-19 Εμβολιο ιου ερπητα ζωστηρα
CY20181100636T CY1121211T1 (el) 2005-03-03 2018-06-19 Εμβολιο ιου ερπητα ζωστηρα
CY2018025C CY2018025I2 (el) 2005-03-03 2018-09-17 Εμβολιο ιου ερπητα ζωστηρα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100179T CY1116108T1 (el) 2005-03-03 2015-02-20 Εμβολιο ιου ερπητα ζωστηρα

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY20181100637T CY1120347T1 (el) 2005-03-03 2018-06-19 Εμβολιο ιου ερπητα ζωστηρα
CY20181100636T CY1121211T1 (el) 2005-03-03 2018-06-19 Εμβολιο ιου ερπητα ζωστηρα
CY2018025C CY2018025I2 (el) 2005-03-03 2018-09-17 Εμβολιο ιου ερπητα ζωστηρα

Country Status (35)

Country Link
US (3) US20080171079A1 (el)
EP (4) EP2281831B1 (el)
JP (2) JP5420842B2 (el)
KR (2) KR20140006115A (el)
CN (2) CN103028113B (el)
AR (2) AR052498A1 (el)
AU (1) AU2006222225B2 (el)
BR (1) BRPI0607840B1 (el)
CA (2) CA2600905C (el)
CY (5) CY1116108T1 (el)
DK (4) DK2301955T3 (el)
EA (1) EA011884B1 (el)
ES (4) ES2675055T3 (el)
GB (1) GB0504436D0 (el)
HK (1) HK1111427A1 (el)
HR (4) HRP20150142T1 (el)
HU (4) HUE038468T2 (el)
IL (1) IL185442A (el)
LT (4) LT2301955T (el)
LU (1) LUC00087I2 (el)
MA (1) MA29714B1 (el)
MX (2) MX2007010626A (el)
MY (1) MY148464A (el)
NL (1) NL300951I2 (el)
NO (2) NO341841B1 (el)
NZ (1) NZ561075A (el)
PE (2) PE20061287A1 (el)
PL (4) PL2281830T3 (el)
PT (4) PT1858917E (el)
SI (4) SI2301955T1 (el)
TR (2) TR201809397T4 (el)
TW (1) TWI403517B (el)
UA (1) UA94900C2 (el)
WO (1) WO2006094756A2 (el)
ZA (1) ZA200707144B (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US20100330122A1 (en) * 2007-07-19 2010-12-30 Gale Smith VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
EP2590626B1 (en) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
HRP20221023T1 (hr) 2010-08-31 2022-11-11 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za isporuku rna koja kodira imunogen
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3053591A4 (en) * 2013-10-03 2017-04-19 Nitto Denko Corporation Injectable vaccine composition
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
CN107106675A (zh) * 2014-12-18 2017-08-29 葛兰素史密丝克莱恩生物有限公司 疫苗接种
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
TW201729838A (zh) * 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US10874734B2 (en) 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3560512A4 (en) * 2016-12-26 2020-07-22 Mogam Institute for Biomedical Research COMPOSITION OF VACCINE AGAINST ZONA
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
IL292991A (en) * 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
KR20200098476A (ko) 2017-10-16 2020-08-20 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌 유사체
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
JP7247226B2 (ja) * 2018-05-23 2023-03-28 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113164586B (zh) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
US20230073321A1 (en) * 2019-12-13 2023-03-09 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical composition and use thereof
KR20210110242A (ko) * 2020-02-28 2021-09-07 (주)셀트리온 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물
WO2022031359A1 (en) 2020-08-07 2022-02-10 Infectious Disease Research Institute Purified saponins and chromatographic process for purification of same
KR102660479B1 (ko) * 2020-09-11 2024-04-25 주식회사 유바이오로직스 수두 또는 대상포진 백신 조성물 및 이를 이용하는 방법
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
EP4416274A2 (en) 2021-10-15 2024-08-21 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
EP4436983A1 (en) 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Varicella-zoster virus immunogen compositions and their uses
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (el) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE119939T1 (de) 1989-06-27 1995-04-15 Smithkline Beecham Biolog Verbindungen.
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
DK0651789T4 (da) * 1992-07-17 2009-07-27 Merck & Co Inc Fremgangsmåde til at forebygge zoster eller lindre varicella-forbundet post-herpetisk neuralgia
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
CN1259052A (zh) 1997-04-01 2000-07-05 科里克萨有限公司 单磷酰基脂质a的水性免疫佐剂组合物
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
PL208755B1 (pl) * 2000-10-18 2011-06-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
WO2006094756A2 (en) 2006-09-14
AR107285A2 (es) 2018-04-18
CY2018025I1 (el) 2018-12-12
TWI403517B (zh) 2013-08-01
EP1858917A2 (en) 2007-11-28
EP1858917B1 (en) 2014-12-24
AU2006222225A1 (en) 2006-09-14
NL300951I2 (nl) 2020-08-31
NO2018033I1 (no) 2018-09-20
CN103028113B (zh) 2015-05-20
EP1858917B8 (en) 2015-05-06
EP2281831B1 (en) 2018-04-18
BRPI0607840A2 (pt) 2009-06-13
PE20061287A1 (es) 2006-12-07
CA2600905C (en) 2015-05-05
PE20100658A1 (es) 2010-10-23
LTPA2018012I1 (lt) 2018-11-12
SI2281830T1 (sl) 2017-03-31
JP2008531637A (ja) 2008-08-14
CA2600905A1 (en) 2006-09-14
ES2618037T3 (es) 2017-06-20
HUE032544T2 (en) 2017-10-30
PT2301955T (pt) 2018-06-18
PL2301955T3 (pl) 2018-08-31
HRP20180988T1 (hr) 2018-08-10
SI2281831T1 (en) 2018-07-31
AU2006222225B2 (en) 2012-08-16
CY1120347T1 (el) 2018-12-12
AR052498A1 (es) 2007-03-21
DK2301955T3 (en) 2018-06-14
HK1111427A1 (en) 2008-08-08
LTC2281831I2 (lt) 2020-08-25
SI1858917T1 (sl) 2015-03-31
IL185442A (en) 2013-07-31
TR201809393T4 (tr) 2018-07-23
EP2281831A2 (en) 2011-02-09
EA011884B1 (ru) 2009-06-30
HUS1800038I1 (hu) 2018-10-29
ES2675054T3 (es) 2018-07-06
BRPI0607840B1 (pt) 2021-06-29
PT1858917E (pt) 2015-02-24
MA29714B1 (fr) 2008-09-01
EA200701632A1 (ru) 2008-02-28
LT2281830T (lt) 2017-02-10
JP2013144710A (ja) 2013-07-25
DK2281831T3 (en) 2018-06-14
HRP20150142T1 (hr) 2015-05-22
KR20070110413A (ko) 2007-11-16
CA2882255C (en) 2018-03-27
EP2301955A3 (en) 2011-11-16
GB0504436D0 (en) 2005-04-06
ES2675055T3 (es) 2018-07-06
HRP20180989T1 (hr) 2018-08-10
US20080171079A1 (en) 2008-07-17
KR101357204B1 (ko) 2014-02-06
TW200643028A (en) 2006-12-16
US7939084B1 (en) 2011-05-10
NO341841B1 (no) 2018-02-05
US20110045059A1 (en) 2011-02-24
LT2301955T (lt) 2018-07-10
IL185442A0 (en) 2008-01-06
DK1858917T3 (da) 2015-02-02
NL300951I1 (nl) 2018-09-26
JP5420842B2 (ja) 2014-02-19
LT2281831T (lt) 2018-07-10
CN101189254A (zh) 2008-05-28
MX346865B (es) 2017-04-04
CN103028113A (zh) 2013-04-10
PL2281831T3 (pl) 2018-08-31
EP2281830A3 (en) 2012-01-25
NO20074392L (no) 2007-11-27
LUC00087I2 (el) 2018-11-26
HUE038467T2 (hu) 2018-10-29
EP2301955A2 (en) 2011-03-30
ZA200707144B (en) 2009-11-25
EP2281830B1 (en) 2016-12-21
CY1121211T1 (el) 2020-05-29
SI2301955T1 (en) 2018-07-31
NZ561075A (en) 2009-06-26
WO2006094756A3 (en) 2007-02-15
EP2301955B1 (en) 2018-04-18
CA2882255A1 (en) 2006-09-14
PL1858917T3 (pl) 2015-05-29
DK2281830T3 (en) 2017-03-20
JP5840167B2 (ja) 2016-01-06
PT2281830T (pt) 2017-02-24
US20110104260A1 (en) 2011-05-05
EP2281831A3 (en) 2011-11-16
PT2281831T (pt) 2018-06-15
CN101189254B (zh) 2013-05-22
HUE038468T2 (hu) 2018-10-29
CY1116108T1 (el) 2017-02-08
CY2018025I2 (el) 2018-12-12
MX2007010626A (es) 2007-10-16
EP2281830A2 (en) 2011-02-09
PL2281830T3 (pl) 2017-06-30
MY148464A (en) 2013-04-30
KR20140006115A (ko) 2014-01-15
HRP20170081T1 (hr) 2017-03-24
ES2532803T3 (es) 2015-03-31

Similar Documents

Publication Publication Date Title
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
CR10101A (es) Nueva composición
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
DE60142615D1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
NO20090897L (no) Vaksine
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
WO2008096831A1 (ja) 癌の治療剤
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
AR108718A2 (es) Composición
BR112023019301A2 (pt) Formulações de vacina de coronavírus
GB2444676A (en) Adjuvanted vaccine
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
ATE535253T1 (de) Impfstoff gegen mycoplasma prrsv
WO2007028985A3 (en) Adjuvanted vaccine
WO2007150054A3 (en) Immunogenic compositions having altered glycosylations
WO2007025276A3 (en) Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
EP2433648A3 (en) Vaccine comprising an oil in water emulsion adjuvant
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
FR2893254B1 (fr) Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique.